RVLM Sympathetic Neurons

Rostral Ventrolateral Medulla Sympathetic Neurons in Neurodegeneration

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">RVLM Sympathetic Neurons</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Ventrolateral medulla, caudal to pons</td>
</tr>
<tr>
<td class="label">Boundaries</td>
<td>Inferior olive (dorsal), pyramids (medial)</td>
</tr>
<tr>
<td class="label">Cell groups</td>
<td>C1 adrenergic + non-catecholaminergic</td>
</tr>
<tr>
<td class="label">Projections</td>
<td>Ipsilateral IML of spinal cord</td>
</tr>
<tr>
<td class="label">Blood supply</td>
<td>Penetrating branches of vertebral/basilar</td>
</tr>
<tr>
<td class="label">System</td>
<td>Effect on RVLM</td>
</tr>
<tr>
<td class="label">Glutamate</td>
<td>Excitatory</td>
</tr>
<tr>
<td class="label">GABA</td>
<td>Inhibitory</td>
</tr>
<tr>
<td class="label">Glycine</td>
<td>Inhibitory</td>
</tr>
<tr>
<td class="label">Serotonin</td>
<td>Excitatory</td>
</tr>
<tr>
<td class="label">Angiotensin II</td>
<td>Excitatory</td>
</tr>
<tr>
<td class="label">[Acetylcholine](/entities/acetylcholine)</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Orthostatic hypotension</td>
<td>Sympathetic denervation</td>
</tr>
<tr>
<td class="label">Supine hypertension</td>
<td>Resid

Rostral Ventrolateral Medulla Sympathetic Neurons in Neurodegeneration

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">RVLM Sympathetic Neurons</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Ventrolateral medulla, caudal to pons</td>
</tr>
<tr>
<td class="label">Boundaries</td>
<td>Inferior olive (dorsal), pyramids (medial)</td>
</tr>
<tr>
<td class="label">Cell groups</td>
<td>C1 adrenergic + non-catecholaminergic</td>
</tr>
<tr>
<td class="label">Projections</td>
<td>Ipsilateral IML of spinal cord</td>
</tr>
<tr>
<td class="label">Blood supply</td>
<td>Penetrating branches of vertebral/basilar</td>
</tr>
<tr>
<td class="label">System</td>
<td>Effect on RVLM</td>
</tr>
<tr>
<td class="label">Glutamate</td>
<td>Excitatory</td>
</tr>
<tr>
<td class="label">GABA</td>
<td>Inhibitory</td>
</tr>
<tr>
<td class="label">Glycine</td>
<td>Inhibitory</td>
</tr>
<tr>
<td class="label">Serotonin</td>
<td>Excitatory</td>
</tr>
<tr>
<td class="label">Angiotensin II</td>
<td>Excitatory</td>
</tr>
<tr>
<td class="label">[Acetylcholine](/entities/acetylcholine)</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Orthostatic hypotension</td>
<td>Sympathetic denervation</td>
</tr>
<tr>
<td class="label">Supine hypertension</td>
<td>Residual sympathetic activity</td>
</tr>
<tr>
<td class="label">Nocturnal polyuria</td>
<td>Loss of circadian ADH</td>
</tr>
<tr>
<td class="label">Anhidrosis</td>
<td>Sympathetic cholinergic loss</td>
</tr>
<tr>
<td class="label">Urinary symptoms</td>
<td>Bladder dysfunction</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Pathophysiology</td>
</tr>
<tr>
<td class="label">Orthostatic hypotension</td>
<td>Sympathetic denervation</td>
</tr>
<tr>
<td class="label">Cardiac denervation</td>
<td>Postganglionic loss</td>
</tr>
<tr>
<td class="label">Baroreflex impairment</td>
<td>Central integration failure</td>
</tr>
<tr>
<td class="label">Constipation</td>
<td>Enteric + central</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>PD</td>
</tr>
<tr>
<td class="label">OH severity</td>
<td>Mild-moderate</td>
</tr>
<tr>
<td class="label">Cardiac denervation</td>
<td>Postganglionic</td>
</tr>
<tr>
<td class="label">Levodopa effect</td>
<td>May improve</td>
</tr>
<tr>
<td class="label">Prognosis</td>
<td>Better</td>
</tr>
<tr>
<td class="label">Cardiac MIBG</td>
<td>Reduced</td>
</tr>
<tr>
<td class="label">Change</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Reduced C1 neurons</td>
<td>↓ Sympathetic drive</td>
</tr>
<tr>
<td class="label">Decreased TH</td>
<td>↓ Catecholamine synthesis</td>
</tr>
<tr>
<td class="label">GABA dysregulation</td>
<td>Impaired baroreflex</td>
</tr>
<tr>
<td class="label">Glutamate excess</td>
<td>Excitotoxic damage</td>
</tr>
<tr>
<td class="label">Test</td>
<td>Parameter</td>
</tr>
<tr>
<td class="label">Tilt table</td>
<td>OH severity</td>
</tr>
<tr>
<td class="label">Valsalva</td>
<td>Baroreflex function</td>
</tr>
<tr>
<td class="label">Deep breathing</td>
<td>Heart rate variability</td>
</tr>
<tr>
<td class="label">QSART</td>
<td>Sudomotor function</td>
</tr>
<tr>
<td class="label">Plasma norepinephrine</td>
<td>Supine/standing</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Fludrocortisone</td>
<td>Volume expansion</td>
</tr>
<tr>
<td class="label">Midodrine</td>
<td>α1 agonist</td>
</tr>
<tr>
<td class="label">Droxidopa</td>
<td>NE precursor</td>
</tr>
<tr>
<td class="label">Pyridostigmine</td>
<td>Enhance ganglionic transmission</td>
</tr>
<tr>
<td class="label">Compression garments</td>
<td>Reduce venous pooling</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Atomoxetine</td>
<td>Presynaptic NE reuptake</td>
</tr>
<tr>
<td class="label">Ampreloxetine</td>
<td>NE transporter inhibition</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Sympathetic neuron support</td>
</tr>
<tr>
<td class="label">Stem cells</td>
<td>Neuron replacement</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Central (MSA)</td>
</tr>
<tr>
<td class="label">OH onset</td>
<td>Subacute</td>
</tr>
<tr>
<td class="label">Motor symptoms</td>
<td>Present</td>
</tr>
<tr>
<td class="label">Sweating</td>
<td>Reduced globally</td>
</tr>
<tr>
<td class="label">MIBG uptake</td>
<td>Preserved</td>
</tr>
<tr>
<td class="label">Progression</td>
<td>Rapid</td>
</tr>
</table>

Overview

The rostral ventrolateral medulla (RVLM) contains presympathetic [neurons](/entities/neurons) that are the primary source of excitatory drive to the spinal sympathetic preganglionic neurons. These neurons are critical for maintaining basal vasomotor tone, blood pressure homeostasis, and autonomic regulation. In neurodegenerative disorders, particularly multiple system atrophy (MSA) and [Parkinson disease](/diseases/parkinsons-disease) (PD), RVLM dysfunction contributes to severe autonomic manifestations including orthostatic hypotension, blood pressure fluctuations, and sudden death risk.

RVLM Neuroanatomy

Anatomical Organization

The RVLM is located in the ventrolateral medullary reticular formation:

C1 Adrenergic Neurons

The C1 cell group within the RVLM is the primary source of bulbospinal catecholaminergic projections:

• Neurotransmitters: Epinephrine, norepinephrine, glutamate
• Synthesis enzymes: TH, DBH, PNMT
• Markers: Tyrosine hydroxylase, phenylethanolamine N-methyltransferase
• Firing pattern: Pacemaker-like spontaneous activity
• Target: Intermediolateral cell column (IML) at T1-L2

Non-C1 Neurons

A substantial proportion of RVLM presympathetic neurons are non-catecholaminergic:

• Primary transmitter: Glutamate (VGLUT2 expressing)
• Peptide co-transmitters: Substance P, neurokinin B
• Function: Baroreflex integration
• Proportion: ~50% of presympathetic neurons

Physiological Functions

Vasomotor Tone Generation

RVLM neurons maintain basal sympathetic tone through:

Baroreflex Circuit

Neurotransmitter Systems

Role in Multiple System Atrophy

Autonomic Failure Mechanism

MSA is characterized by severe autonomic dysfunction driven by RVLM pathology:

• Neuronal loss: Progressive C1 neuron degeneration
• Gliosis: Reactive astrocytosis in RVLM
• GCIs: Glial cytoplasmic inclusions with [α-synuclein](/proteins/alpha-synuclein)
• Connectivity disruption: Loss of bulbospinal projections

Clinical Manifestations

Cardiovascular Instability

• OH severity: Often >60 mmHg SBP drop on standing
• Postprandial hypotension: Blood pooling in splanchnic circulation
• Exercise intolerance: Blunted cardiac response
• Sudden death: Arrhythmia, apnea risk

Role in Parkinson Disease

Autonomic Dysfunction Spectrum

PD autonomic features reflect varying RVLM involvement:

Comparison with MSA

Sudden Death Risk

RVLM dysfunction in PD/MSA increases mortality:

Molecular Pathophysiology

α-Synuclein Pathology

In MSA, glial cytoplasmic inclusions affect RVLM:

• Oligodendroglial GCIs: α-Synuclein aggregates
• Neuronal dysfunction: Secondary to glial pathology
• Mitochondrial impairment: Oxidative stress
• Excitotoxicity: Glutamate dysregulation

Neurotransmitter Changes

Inflammatory Mechanisms

• Microglial activation: Neuroinflammation in RVLM
• Cytokine elevation: IL-1β, TNF-α in brainstem
• Complement activation: Membrane attack complex
• Astrogliosis: Reactive astrocyte response

Clinical Assessment

Autonomic Testing

Neuroimaging

• Cardiac MIBG: Postganglionic denervation in PD
• Cardiac PET: Sympathetic innervation assessment
• Brain MRI: Brainstem atrophy in MSA
• fMRI: RVLM functional connectivity

Therapeutic Approaches

Orthostatic Hypotension Management

Non-Pharmacological Strategies

Emerging Therapies

Differential Diagnosis

Central vs Peripheral Autonomic Failure

Brainstem Disorders Affecting RVLM

• Lateral medullary syndrome: Wallenberg syndrome
• Brainstem tumors: Compression/infiltration
• Syringobulbia: Cavity extension
• Multiple sclerosis: Brainstem plaques

Research Directions

Biomarker Development

• Microneurography: Direct sympathetic recording
• Heart rate variability: Autonomic function markers
• Plasma biomarkers: [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain
• Imaging biomarkers: Brainstem volumetry

Pathogenic Mechanisms

See Also

• [Cell Types Index](/cell-types)
• [Brain Regions Index](/brain-regions)
• [Diseases Index](/diseases)
• [Mechanisms Index](/mechanisms)

External Links

• [Allen Brain Atlas](https://portal.brain-map.org/)
• [BrainSpan Atlas](https://www.brainspan.org/)
• [Human Cell Atlas](https://www.humancellatlas.org/)

References

benarroch2019, The clinical neurology of autonomic failure (2019)
coon2022, Sudden death in synucleinopathies: autonomic and sleep mechanisms (2022)
goldstein2006, Orthostatic hypotension as an early finding in Parkinson disease (2006)
guyenet2017, The C1 neurons of the RVLM: essential for the baroreflex and the sympathetic response to stress (2017)
kaufmann2014, Droxidopa for neurogenic orthostatic hypotension (2014)
low2008, Autonomic dysfunction in multiple system atrophy (2008)
orimo2006, Cardiac sympathetic denervation in Lewy body disease (2006)
schreihofer2013, The ventrolateral medulla and sympathetic regulation of arterial pressure (2013)

Pathway Diagram

The following diagram shows the key molecular relationships involving RVLM Sympathetic Neurons discovered through SciDEX knowledge graph analysis: